Kimberly Blackwell, MD

Trials

Studies that name Kimberly Blackwell, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:12 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT03045393 · Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

  Duke University · withdrawn · Breast Cancer Triple Negative · principal investigator
• Ph1
  NCT02598427 · Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

  Kimberly Blackwell · terminated · HER2 Positive Untreated Metastatic Breast Cancer, Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer · principal investigator
• Ph2
  NCT00546104 · Phase II Dasatinib Study in Advanced Breast Cancer

  Duke University · completed · Advanced Breast Cancer · principal investigator
• Ph2
  NCT00479674 · Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

  Duke University · completed · Breast Cancer · principal investigator
• Ph2
  NCT00476827 · A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

  Duke University · terminated · Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 13:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.